Printer Friendly

First 1,000 cases of gamma knife surgery for various intracranial disorders in LSU health-Shreveport: radiological and clinical outcome.

INTRODUCTION

Radiosurgeries including gamma knife radiosurgery (GKRS), linear accelerators and cyclotrons have emerged as important treatment options for the management of variousdisorders. (1-3) Numerous studies, including retrospective and prospective series, reported the safety and efficacy of GKRS alone or as an adjunct therapy with microsurgery or conventional radiotherapy. (4-6) GKRS delivers a high single procedural radiation dose to a target volume of tumor or vascular malformation and provides various beneficial effects including excellent control of local tumor or nidus growth, shorter hospital stay, lower cost, lower mortality and morbidity, minimum invasiveness, and wide access of GKRS for repeated treatments. (7-8) GKRS can successfully treat the patients with various intracranial tumors including metastatic brain tumors (MBTs), meningiomas, vestibular schwannomas (VS), astrocytomas and pituitary adenomas etc. (1,9,10) Similarly, GKRS can be used to treat intracranial vascular disorder such as arteriovenous malformation (AVM), arteriovenous fistulas and cavernous malformation. (11-13) In addition, GKRS can also be an important treatment option for other miscellaneous disorders including trigeminal neuralgia (TGN), epilepsy and tremor. (14-16) However, there is no summarized information in existing literature about the effect of GKRS in the above mentioned diseases. In the present study, we retrospectively reviewed our experience in the management, outcome and complications of first 1,017 GKRS in various disorders.

MATERIALS AND METHODS

This study was done after approval by the Institutional Review Board at LSU Health-Shreveport, Louisiana. Information related to clinical history, microsurgery, radiotherapy, GKRS, neuroimaging including MRI, and outcomes of the patients with various intracranial lesions between 2000 and 2013 were collected retrospectively by review of the patients' case reports and follow-up charts.

PATIENTS AND TUMOR CHARACTERISTICS

There were 1,017 GKRSs in 911 patients with various disorders. The patients' characteristics and distribution of different disorders among the patients are described in Table 1.

RADIOSURGICAL TECHNIQUE

GKRS was performed using the Leksell stereotactic unit; model "C" with automatic positioning system, manufactured in Atlanta, Georgia. The Leksell head frame was placed on the patient's head while the patient was under IV sedation and local anesthesia. The patient was then transferred to the MRI suite for imaging. High resolution contrast enhanced axial pictures of the brain were taken in the 3-D SPGR sequence. The imaging data was then transferred to the gamma knife planning computer via the ethernet. The Leksell Gamma Plan software version 5.34 was used to perform the dose planning. A management team including neurosurgeon, medical physicist and radiation oncologist performed dose selection and planning.

DOSING PLAN OF THE GKRS FOR VARIOUS INTRACRANIAL LESIONS

Vestibular schwannoma:

The median marginal dose to the schwannoma was 13Gy (range 8-20), maximum dose to the schwannoma was 24Gy (range 16-40), and median 50% isodose line was 50% (range 15-100). Median radiation exposure time was 36 minutes (range 4-98).

Meningioma:

The median marginal dose to the meningioma was 14Gy (range 12-30), maximum dose to the meningioma was 28Gy (range 24-60), and the median 50% isodose line was 50% (range 50-80). Median radiation exposure time was 35 minutes (range 4-94).

MBTs:

The median marginal dose to the MBTs was 16Gy (range 7-22), maximum dose to the MBTs was 32Gy (range 14-44), and the median 50% isodose line was 50% (range 40-70). Median radiation exposure time was 29 minutes (range 4-95).

Astrocytomas:

The median marginal dose to the astrocytomas was 14Gy (range 10-20), maximum dose to the astrocytomas was 28Gy (range 20-40), and the median 50% isodose line was 50% (range 40-50). Median radiation exposure time was 30 minutes (range 4-56).

Pituitary Adenomas:

The median marginal dose to the pituitary adenomas was 15Gy (range 8-20), maximum dose to the pituitary adenomas was 30Gy (range 16-40), and the median 50% isodose line was 50% (range 30-54). Median radiation exposure time was 45 minutes (range 4-94).

AVM :

The median marginal dose to the AVM was 18Gy (range 14-25), maximum dose to the AVM was 36Gy (range 28-50), and the median 50% isodose line was 50% (range 50-60). Median radiation exposure time was 32 minutes (range 12-82).

TGN:

The median maximum dose to the TGN was 80Gy (range 60-90), and median 100% isodose line was 100%. Median radiation exposure time was 44 minutes (range 24-90).

FOLLOW-UP

Preoperative and follow-up data were collected from the patients in this study from patient's notes and follow-up charts. Follow-up was performed at three month intervals in the first year of the GKRS treatment, at six month intervals for following two years and annually thereafter for detailed neurological examination to demonstrate the improvement or worsening of preexisting signs and symptoms, development of any new sign and symptom, and any change in images. The mean and median follow-up time for each lesion was as follows. Meningioma: mean and median follow-up time was 63.71 and 61 months (range, 6-158). Schwannoma: mean and median follow-up time was 59.53 and 49 months (range, 6-149). MBTs: mean and median follow-up time was 18 and 9 months (range, 3-137). Astrocytomas: mean and median follow-up time was 9.2 and 7.2 months (range, 3-32). Pituitary adenomas: mean and median follow-up time was 45 and 30.48 months (range, 2.5-157). AVM: mean and median follow-up time was 32.65 and 35.23 months (range, 3-134).TGN: mean and median follow-up time was 38.73 and 33.16 months (range, 2-151).

STATISTICAL ANALYSIS

Commercially available software, SPSS version 21.0 (SPSS, Inc., Chicago, Illinois), was used for statistical analysis. Overall survival and progression free survival were analyzed using the Kaplan Meier test. The log-rank (Mantel-Cox) test was used to analyze the survival difference in the cases. Cox regression model was used to demonstrate the predictive factors of the outcome Univariate analysis was performed to indentify the predictive factors for obliteration of AVM and pain relief in TGN. A Chi square test was also used when applicable. A p value <0.05 was considered as significant.

DISCUSSION

Benign and malignant intracranial tumors and vascular malformations can cause disability with neurological deficits and death in the patients who harbor them. This kind of damage provokes a significant cost to society. (17) In the past decades, patients with intracranial tumors, vascular malformation and functional disorders were managed primarily with microsurgical resection or radiation therapy. (18,24) Even after recurrence of the tumors following primary therapies, repeat resection was considered. However, GKRS became a popular therapeutic option for the many patients with intracranial tumors, vascular malformations and functional neurological disorders. (1,9,24,25) In our case series, we planned to demonstrate the clinical outcome, radioimaging changes in the lesions, complications and predictive factors of improvement in the patients after GKRS. Each lesion in the brain posed unique clinical challenges with the varieties of the issues including volume and location of the tumors or AVM nidus, radiation dosing etc. Therefore, we have kept the track of the radiological and clinical outcomes of each lesion separately which is described below.

Vestibular Schwannoma:

The radiological and clinical outcome of GKRS in the patients with VS is described in Table 2. In this retrospective study, the overall control of VS growth was 90% after GKRS which was consistent with previous studies. (26,27) The progression free survival rate was 90% 10 years after GKRS, which was consistent with an earlier report. (27) In our case series, the preservation of hearing after GKRS was 80% which was supported by previous studies (range, 38%-94%). (28-29) Likewise, consistent with an earlier report, (27) this study revealed the significant lower rate of facial nerve affection (6%) after GKRS in the overall number of patients. Four percent of patients experienced trigeminal neuropathy which was comparable with a previous report 30. Moreover, the present study also determined that overall quality of life was improved after GKRS which could be due to improvement in signs and symptoms of the disease including ataxia, hearing loss and impairment facial nerve function. (31) The present study did not reveal any major complications such as hydrocephalus and edema after GKRS in new patients. Thus, GKRS is beneficial for VS either as a primary or adjuvant therapy.

Meningioma:

The radiological and clinical outcome of GKRS in the patients with meningiomas is reported in the Table 3. In the present study, the average tumor control was 86% after GKRS in new (91%) and recurrent (81%) patients, which was comparable with other previous reports (range, 75-100% of tumor growth control). (32-33) The less favorable results of GKRS on recurrent meningiomas usually depend on the characteristics and Simpson grades of tumor resection. (34) Consistent with an earlier report, this study showed that the progression free survival rate was 98%, 95% and 85% at 3, 5 and 10 years respectively after GKRS. (35) The improvement of neurological deficits and other systemic symptoms in affected patients are very important to verify the patient's response to therapy. Findings of this study demonstrated that GKRS therapy improved 30% of total signs and symptoms including visual impairment, facial nerve and trigeminal nerve dysfunctions, which was comparable with a previous report. (36) This study also noted that overall quality of life in the patients was significantly improved after GKRS which could be due to improvement of visual impairment and facial nerve dysfunction. (37) The present study showed complications including hydrocephalus, seizure, preexisting visual problem, ataxia, etc. after GKRS; comparable with a previous study. (37) Therefore, GKRS is an important treatment option for meningioma either as a primary or adjuvant therapy. (38)

Metastatic Brain Tumors:

The radiological and clinical outcome of GKRS in the patients with MBTs is represented in the Table 4. In the present case series, the median overall survival after GKRS in MBTs was 17 months which was comparable with earlier reports (range 9-18 months). (39-41) The Cox regression analysis identified hydrocephalus (p < 0.0001, RPA class (p < 0.0001), recurrent MBTs (p = 0.01) and KPS (p = 0.007) as the predictors of survival, which was consistent with previous studies. (5,42-43) This study demonstrated that the tumor growth control occurred in 76% patients, which is fairly comparable with the range of 70-100% as reported by a previous study. (40) Forty (13.4%) patients required GKRS, 15 (5.0%) patients required resection and 2 (0.6%) patients required well-being therapy (WBT) after initial GKRS due to newly developed lesions and complications (e.g. hydrocephalus, hemorrhage) which was consistent with the earlier report. (45) Lastly, GKRS is an important treatment option for MBTs but the timing of treatment for recurrent cases needs to be further investigated.

Astrocytoma:

The outcome of GKRS on astrocytomas is noted in Table 5. The average tumor size was 11.1 cm3 in the entire cohort. There are conflicting results regarding the overall survival benefits following GKRS therapy for astrocytomas. (46-48) Results of GKRS on astrocytomas depend on tumor size. The median overall survival in our series was 18.2 months from diagnosis and 7.25 from recurrence, which is lower than another previous report (49) on MBTs with GKRS (18.2 vs. 26 months). Our finding is consistent with previous reports. (47,50) Our series showed that overall survival rate at 1 year, 2 years and 3 years from diagnosis of the disease was 75%, 35% and 20% respectively, which is consistent with a previous report p=examining GKRS at time of recurrence. (46) Cox regression analysis also identified age Y 50yr (p = 0.008), KPS > 70 (p = 0.034), prior external beam radiation therapy (p = 0.042), absence of neurodeficits (p=0.013) and GKRS at recurrence of tumor (p = 0.023) as the positive predictors of the survival which is consistent with earlier reports. (46-51) Unfortunately, data in our case series confirms that the overall prognosis of GBM remains dismal. Despite attempting to attain local tumor growth control with GKRS, 75% patients in our series had tumor progression during the follow-up period. Comparable to our study, previous studies have demonstrated that the failure rate of local tumor growth control was 78% to 90%. (48-51) Although our morbidity and mortality is high for a GKRS series, this reflects our practice pattern of referring high-risk patients with recurrence for GKRS treatment prior to considering more invasive treatments like repeat microsurgical resection. Therefore, GKRS is an important treatment option for astrocytoma as an adjunct therapy during progression time of the tumors.

Pituitary Adenoma:

The clinical and radiological outcome of GKRS on pituitary adenoma is described in Table 6. Recent large GKRS series for pituitary adenomas showed 87-97% local tumor growth control and 42-78% tumor regression. Our study demonstrated that the overall tumor growth control rate was 93%, and that the progression free survival rate at 3, 7 and 10 years was 100%, 95% and 90% respectively, which are very consistent with previous studies. (52-54) Although 95% of patients demonstrated preservation of visual functions, 5% of patients showed some degree of preexisting or newly developed visual impairment which is consistent with previous reports. (55,56) New cranial nerve III palsy was observed in 2 (2.1%) patients in this case series, which is also consistent with earlier study. (53) The present study revealed that 12% of the patients developed hypopituitarism after GKRS therapy which is comparable with a previous report. (56) The present study also showed that overall quality of life was improved (KPS, pre-GKRS, 87 vs. post-GKRS, 94) after GKRS which could be due to improvement in signs and symptoms of the disease including visual impairment and neurodeficits. Although complications including radionecrosis, CVA and neoplasia were not found in our series, hydrocephalus was observed in one patient, and that is comparable to an earlier study. (56) Thus, GKRS is a good option to treat pituitary adenomas.

AVM:

The outcome of GKRS on AVM is reported in Table 7. Obliteration of nidus volume is important after GKRS on AVM. This case series demonstrated that the obliteration of the nidus was 79%, which is very consistent with earlier studies with 65-95% of nidus obliteration. (57-58) The usual period of nidus obliteration is 2-3 years and our series showed that the median time of nidus obliteration was 31 months which is also comparable with the earlier studies. (59) In univariate analysis, although Spetzler-Martin grade I-III (p = 0.002), female gender (p = 0.02) and absence of neurodeficit (p = 0.01) were significant for nidus obliteration in our case series, prior hemorrhage (p = 0.27) and embolization (p = 0.24) did not show any significant relation with nidus obliteration. These are consistent with previous series. (60,61) There are few complications in our series including hemorrhage, hydrocephalus, neurodeficits, seizure and cystic degeneration after GKRS which are comparable with previous series. (61-63) Therefore, GKRS is a good therapeutic option to treat AVM.

TGN:

The clinical outcome and predictive factors of GKRS in the patients with TGN is described in Table 8. The present study showed that TGN pain was completely relieved in 94 (55.6%) patients, partially relived in 38 (22.4%) patients and aggravated in 37 (22%) patients which was very consistent with our earlier report and other published studies. (64-66) In univariate analysis, age <70 years was significant for pain relief in our case series, and gender, ethnicity and pain distribution had no significant relation with resolution of pain which is also consistent with earlier report. (65) Thus, GKRS is a good therapeutic option to treat TGN.

LIMITATION

The strengths of this study include using of the Leksell Gamma Plan software version 5.34 for determination of radiation dose-volume, and single fraction GKRS technique for entire cohort. Despite having a large number of patients with long term follow-up, this study also has a few limitations that could influence the external validity of the study. First, this study was single-center, retrospective design. Second, there was lack of a true control group in this study. Third, slightly variability in the standard treatment offered to patients. Fourth, the median follow-up time for several disorders including NFPAs, AVM and TGN was less than 36 months which is inadequate to exclude the late complications of GKRS. Lastly, although majority of the patients were observed by other subspecialists including neuro-ophthalmologists or oncologists after GKRS, we did not comply their strict protocols before and after GKRS. However, this study allows clinicians a guide for the treatment strategies of GKRS for the treatment of various intracranial lesions.

CONCLUSION

Taken together, given the good control of different tumor growth, obliteration of AVM nidus and trigeminal neuralgia pain, good overall and progression free survival rate, possible preservation of neurological functions, lesser number of complications, and improvement of quality of life, GKRS is an important treatment option for patients with different benign tumors, AVM and trigeminal neuralgia. In addition, GKRS can also be a good treatment option for patients with recurrent benign tumors, AVM and trigeminal neuralgia to avoid repeated microsurgical resections along with craniotomy related complications. However, as of now, GKRS is not so effective for recurrent malignant tumors. Further randomized controlled studies with a large volume of patients with various tumors, AVM and trigeminal neuralgia are required to accomplish a good comparison of treatment modalities.

Shyamal C. Bir MD, PhD; Tabitha Ward MS; Papireddy Bollam MD; Anil Nanda MD, MPH

REFERENCES

(1.) Sneed PK, Suh JH, Goetsch SJ, Sanghavi SN, Chappell R, Buatti JM, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys. 2002;53(3):519-526. PubMed PMID: 12062592.

(2.) Friedman WA, Murad GJ, Bradshaw P, Amdur RJ, Mendenhall WM, Foote KD, et al. Linear accelerator surgery for meningiomas. J Neurosurg. 2005;103(2):206-209. doi: 10.3171/jns.2005.103.2.0206. PubMed PMID: 16175847.

(3.) Weber DC, Chan AW, Bussiere MR, Harsh GRt, Ancukiewicz M, Barker FG, 2nd, et al. Proton beam radiosurgery for vestibular schwannoma: tumor control and cranial nerve toxicity. Neurosurgery. 2003;53(3):577-586;discussion 86-88. PubMed PMID: 12943574.

(4.) Sanghavi SN, Miranpuri SS, Chappell R, Buatti JM, Sneed PK, Suh JH, et al. Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys. 2001;51(2):426-434. PubMed PMID: 11567817.

(5.) Javalkar V, Cardenas R, Ampil F, Ahmed O, Shi R, Nanda A. The Louisiana State University experience in the management of single small cerebellar metastasis. Neurosurgery. 2010;67(6):1515-1522. doi: 10.1227/NEU.0b013e3181fa239e. PubMed PMID: 21107182.

(6.) Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg. 2002;97(6):1276-1281. doi: 10.3171/jns.2002.97.6.1276. PubMed PMID: 12507123.

(7.) Boyd TS, Mehta MP. Radiosurgery for brain metastases. Neurosurg Clin N Am. 1999;10(2):337-350. PubMed PMID: 10099098.

(8.) McDermott MW, Sneed PK. Radiosurgery in metastatic brain cancer. Neurosurgery. 2005;57(5 Suppl):S45-53; discusssion S1-4. PubMed PMID: 16237288.

(9.) Hayashi M, Chernov M, Tamura N, Izawa M, Muragaki Y, Iseki H, et al. Gamma knife robotic microradiosurgery for benign skull base meningiomas: tumor shrinkage may depend on the amount of radiation energy delivered per lesion volume (unit energy). Stereotact Funct Neurosurg. 2011;89(1):6-16. doi: 10.1159/000321184. PubMed PMID: 21124047.

(10.) Kondziolka D, Nathoo N, Flickinger JC, Niranjan A, Maitz AH, Lunsford LD. Long-term results after radiosurgery for benign intracranial tumors. Neurosurgery. 2003;53(4):815-21; discussion 21-22. PubMed PMID: 14519213.

(11.) Lindqvist M, Karlsson B, Guo WY, Kihlstrom L, Lippitz B, Yamamoto M. Angiographic long-term follow-up data for arteriovenous malformations previously proven to be obliterated after gamma knife radiosurgery. Neurosurgery. 2000;46(4):803-808; discussion 9-10. PubMed PMID: 10764252.

(12.) Cifarelli CP, Kaptain G, Yen CP, Schlesinger D, Sheehan JP. Gamma knife radiosurgery for dural arteriovenous fistulas. Neurosurgery. 2010;67(5):1230-1235; discussion 5. doi: 10.1227/ NEU.0b013e3181eff6f7. PubMed PMID: 20871448.

(13.) Lee CC, Pan DH, Chung WY, Liu KD, Yang HC, Wu HM, et al. Brainstem cavernous malformations: the role of Gamma Knife surgery. J Neurosurg. 2012;117 Suppl:164-1699. doi: 10.3171/2012.8.GKS121066. PubMed PMID: 23205805.

(14.) Park KJ, Kondziolka D, Berkowitz O, Kano H, Novotny J, Jr., Niranjan A, et al. Repeat gamma knife radiosurgery for trigeminal neuralgia. Neurosurgery. 2012;70(2):295-305; discussion doi: 10.1227/NEU.0b013e318230218e. PubMed PMID: 21811188.

(15.) Piper RJ, Yoong M, McLellan A, Kandasamy J, Chin RF. Visual field defects after radiosurgery for mesial temporal lobe epilepsy. Epilepsia. 2013;54(11):2019. doi: 10.1111/epi.12385. PubMed PMID: 24199828.

(16.) Kooshkabadi A, Lunsford LD, Tonetti D, Flickinger JC, Kondziolka D. Gamma knife thalamotomy for tremor in the magnetic resonance imaging era. J Neurosurg. 2013;118(4):713-718. doi: 10.3171/2013.1.JNS121111. PubMed PMID: 23373801.

(17.) Martin HC, Sethi J, Lang D, Neil-Dwyer G, Lutman ME, Yardley L. Patient-assessed outcomes after excision of acoustic neuroma: postoperative symptoms and quality of life. J Neurosurg. 2001;94(2):211-216. doi: 10.3171/jns.2001.94.2.0211. PubMed PMID: 11213956.

(18.) Bederson JB, von Ammon K, Wichmann WW, Yasargil MG. Conservative treatment of patients with acoustic tumors. Neurosurgery. 1991;28(5):646-650; discussion 50-51. PubMed PMID: 1876241.

(19.) Borovich B, Doron Y. Recurrence of intracranial meningiomas: the role played by regional multicentricity. J Neurosurg. 1986;64(1):5863. doi: 10.3171/jns.1986.64.1.0058. PubMed PMID: 3941351.

(20.) Breen P, Flickinger JC, Kondziolka D, Martinez AJ. Radiotherapy for nonfunctional pituitary adenoma: analysis of long-term tumor control. J Neurosurg. 1998;89(6):933-938. doi: 10.3171/ jns.1998.89.6.0933. PubMed PMID: 9833818.

(21.) Ellis TL, Neal MT, Chan MD. The role of surgery, radiosurgery and whole brain radiation therapy in the management of patients with metastatic brain tumors. Int J Surg Oncol. 2012;952345. doi: 10.1155/2012/952345. PubMed PMID: 22312545; PubMed Central PMCID: PMC3263703.

(22.) Ashamalla H, Zaki B, Mokhtar B, Lewis L, Lavaf A, Nasr H, et al. Fractionated stereotactic radiotherapy boost and weekly paclitaxel in malignant gliomas clinical and pharmacokinetics results. Technol Cancer Res Treat. 2007;6(3):169-176. PubMed PMID: 17535024.

(23.) Regine W. The radiation oncologist's perspective on stereotactic radiosurgery. Technol Cancer Res Treat. 2002;1(1):43-9. PubMed PMID: 12614176.

(24.) Brown JA. The neurosurgical treatment of neuropathic facial pain. Otolaryngol Clin North Am. 2014;47(2):343-9. doi: 10.1016/j. otc.2013.10.003. PubMed PMID: 24680498.

(25.) Leonbart J. [Compensation and salaries in practice on January 1, 1975]. Osterr Dent Z. 1975;27(3):40-57. PubMed PMID: 1076425.

(26.) Flickinger JC, Kondziolka D, Pollock BE, Lunsford LD. Evolution in technique for vestibular schwannoma radiosurgery and effect on outcome. Int J Radiat Oncol Biol Phys. 1996;36(2):275-280. PubMed PMID: 8892449.

(27.) Hasegawa T, Kida Y, Kobayashi T, Yoshimoto M, Mori Y, Yoshida J. Long-term outcomes in patients with vestibular schwannomas treated using gamma knife surgery: 10-year follow up. J Neurosurg. 2005;102(1):10-16. doi: 10.3171.jns.2005.102.1.0010. PubMed PMID: 15658090.

(28.) Litvack ZN, Noren G, Chougule PB, Zheng Z. Preservation of functional hearing after gamma knife surgery for vestibular schwannoma. Neurosurg Focus. 2003;14(5):e3. PubMed PMID: 15669814.

(29.) Iwai Y, Yamanaka K, Shiotani M, Uyama T. Radiosurgery for acoustic neuromas: results of low-dose treatment. Neurosurgery. 2003;53(2):282-287;discussion 7-8. PubMed PMID: 12925242.

(30.) Ogunrinde OK, Lunsford DL, Kondziolka DS, Bissonette DJ, Flickinger JC. Cranial nerve preservation after stereotactic radiosurgery of intracanalicular acoustic tumors. Stereotact Funct Neurosurg. 1995;64 Suppl 1:87-97. PubMed PMID: 8584844.

(31.) Myrseth E, Moller P, Pedersen PH, Vassbotn FS, Wentzel-Larsen T, Lund-Johansen M. Vestibular schwannomas: clinical results and quality of life after microsurgery or gamma knife radiosurgery. Neurosurgery. 2005;56(5):927-935; discussion -35. PubMed PMID: 15854240.

(32.) Stafford SL, Pollock BE, Foote RL, Link MJ, Gorman DA, Schomberg PJ, et al. Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery. 2001;49(5):1029-1037; discussion 37-38. PubMed PMID: 11846894.

(33.) Spiegelmann R, Nissim O, Menhel J, Alezra D, Pfeffer MR. Linear accelerator radiosurgery for meningiomas in and around the cavernous sinus. Neurosurgery. 2002;51(6):1373-1379; discussion 9-80. PubMed PMID: 12445342.

(34.) Strassner C, Buhl R, Mehdorn HM. Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years? Neurol Res. 2009;31(5):478-482. doi: 10.1179/174313208X3380430. PubMed PMID: 19500450.

(35.) Maire JP, Caudry M, Guerin J, Celerier D, San Galli F, Causse N, et al. Fractionated radiation therapy in the treatment of intracranial meningiomas: local control, functional efficacy, and tolerance in 91 patients. Int J Radiat Oncol Biol Phys. 1995;33(2):315-221. doi: 10.1016/0360-3016(94)00661-4. PubMed PMID: 7673018.

(36.) Kollova A, Liscak R, Novotny J, Jr., Vladyka V, Simonova G, Janouskova L. Gamma Knife surgery for benign meningioma. J Neurosurg. 2007;107(2):325-336. doi: 10.3171/JNS-07/08/0325. PubMed PMID: 17695387.

(37.) Kreil W, Luggin J, Fuchs I, Weigl V, Eustacchio S, Papaefthymiou G. Long term experience of gamma knife radiosurgery for benign skull base meningiomas. J Neurol Neurosurg Psychiatry. 2005;76(10):1425-1430. doi: 10.1136/jnnp.2004.049213. PubMed PMID: 16170090; PubMed Central PMCID: PMC1739368.

(38.) Hasegawa T, Kida Y, Yoshimoto M, Iizuka H, Ishii D, Yoshida K. Gamma Knife surgery for convexity, parasagittal, and falcine meningiomas. J Neurosurg. 2011;114(5): 1392-1398. doi: 10.3171/2010.11.JNS10112. PubMed PMID: 21128736.

(39.) Akyurek S, Chang EL, Mahajan A, Hassenbusch SJ, Allen PK, Mathews LA, et al. Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer. Am J Clin Oncol. 2007;30(3):310-314. doi: 10.1097/01.coc.0000258365.50975.f6. PubMed PMID: 17551311.

(40.) Flannery TW, Suntharalingam M, Kwok Y, Koffman BH, Amin PP, Chin LS, et al. Gamma knife stereotactic radiosurgery for synchronous versus metachronous solitary brain metastases from non-small cell lung cancer. Lung Cancer. 2003;42(3):327-333. PubMed PMID: 14644521.

(41.) Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134-141. doi: 10.1200/JCO.2010.30.1655. PubMed PMID: 21041710; PubMed Central PMCID: PMC3058272.

(42.) Kurtz G, Zadeh G, Gingras-Hill G, Millar BA, Laperriere NJ, Bernstein M, et al. Salvage radiosurgery for brain metastases: prognostic factors to consider in patient selection. Int JRadiat Oncol Biol Phys. 2014;88(1):137-142. doi: 10.1016/j.ijrobp.2013.10.003. PubMed PMID: 24331660.

(43.) Lorenzoni J, Devriendt D, Massager N, David P, Ruiz S, Vanderlinden B, et al. Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys. 2004;60(1):218-224. doi:10.1016/j. ijrobp.2004.02.017. PubMed PMID: 15337559.

(44.) Lippitz B, Lindquist C, Paddick I, Peterson D, O'Neill K, Beaney R. Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. Cancer Treat Rev. 2014;40(1):48-59. doi: 10.1016/j. ctrv.2013.05.002. PubMed PMID: 23810288.

(45.) Williams BJ, Suki D, Fox BD, Pelloski CE, Maldaun MV, Sawaya RE, et al. Stereotactic radiosurgery for metastatic brain tumors: a comprehensive review of complications. J Neurosurg. 2009;111(3):439-448. doi: 10.3171/2008.11.JNS08984. PubMed PMID: 19301968.

(46.) Hsieh PC, Chandler JP, Bhangoo S, Panagiotopoulos K, Kalapurakal JA, Marymont MH, et al. Adjuvant gamma knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme. Neurosurgery. 2005;57(4):684-692; discussion -92. PubMed PMID: 16239880.

(47.) Masciopinto JE, Levin AB, Mehta MP, Rhode BS. Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg. 1995;82(4):530-535. doi: 10.3171/jns.1995.82.4.0530. PubMed PMID: 7897511.

(48.) Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner Wasik M, Lustig R, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. 2004;60(3):853-860. doi: 10.1016/j.ijrobp.2004.04.011. PubMed PMID: 15465203.

(49.) Loeffler JS, Alexander E, 3rd, Shea WM, Wen PY, Fine HA, Kooy HM, et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol. 1992;10(9):1379-1385. PubMed PMID: 1325539.

(50.) Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983;52(6):997-1007. PubMed PMID: 6349785.

(51.) Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery. 2002;51(2):343-355; discussion 55-57. PubMed PMID: 12182772.

(52.) Sheehan JP, Niranjan A, Sheehan JM, Jane JA, Jr., Laws ER, Kondziolka D, et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg. 2005;102(4):678-691. doi: 10.3171/jns.2005.102.4.0678. PubMed PMID: 15871511.

(53.) Park KJ, Kano H, Parry PV, Niranjan A, Flickinger JC, Lunsford LD, et al. Long-term outcomes after gamma knife stereotactic radiosurgery for nonfunctional pituitary adenomas. Neurosurgery. 2011;69(6):1188-1199. doi: 10.1227/NEU.0b013e318222afed. PubMed PMID: 21552167.

(54.) Pollock BE, Carpenter PC. Stereotactic radiosurgery as an alternative to fractionated radiotherapy for patients with recurrent or residual nonfunctioning pituitary adenomas. Neurosurgery. 2003;53(5):1086-1091; discussion 91-94. PubMed PMID: 14580275.

(55.) Abe T, Yamamoto M, Taniyama M, Tanioka D, Izumiyama H, Matsumoto K. Early palliation of oculomotor nerve palsy following gamma knife radiosurgery for pituitary adenoma. Eur Neurol. 2002;47(1):61-63. PubMed PMID: 11803197.

(56.) Sheehan JP, Starke RM, Mathieu D, Young B, Sneed PK, Chiang VL, et al. Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg. 2013;119(2):446-456. doi: 10.3171/2013.3.JNS12766. PubMed PMID: 23621595.

(57.) Lunsford LD, Kondziolka D, Flickinger JC, Bissonette DJ, Jungreis CA, Maitz AH, et al. Stereotactic radiosurgery for arteriovenous malformations of the brain. J Neurosurg. 1991;75(4):512-524. doi: 10.3171/jns.1991.75.4.0512. PubMed PMID: 1885968.

(58.) Ogilvy CS, Stieg PE, Awad I, Brown RD, Jr., Kondziolka D, Rosenwasser R, et al. AHA Scientific Statement: Recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. Stroke. 2001;32(6):1458-1471. PubMed PMID: 11387517.

(59.) Colombo F, Pozza F, Chierego G, Casentini L, De Luca G, Francescon P. Linear accelerator radiosurgery of cerebral arteriovenous malformations: an update. Neurosurgery. 1994;34(1):14-20; discussion -1. PubMed PMID: 8121550.

(60.) Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg. 1986;65(4):476-483. doi: 10.3171/jns.1986.65.4.0476. PubMed PMID: 3760956.

(61.) Zabel-du Bois A, Milker-Zabel S, Huber P, Schlegel W, Debus J. Risk of hemorrhage and obliteration rates of LINAC-based radiosurgery for cerebral arteriovenous malformations treated after prior partial embolization. Int J Radiat Oncol Biol Phys. 2007;68(4):999-1003. doi: 10.1016/j.ijrobp.2007.01.027. PubMed PMID: 17398029.

(62.) Fokas E, Henzel M, Wittig A, Grund S, Engenhart-Cabillic R. Stereotactic radiosurgery of cerebral arteriovenous malformations: long-term follow-up in 164 patients of a single institution. J Neurol. 2013;260(8):2156-2162. doi: 10.1007/s00415-013-6936-6939. PubMed PMID: 23712798.

(63.) Pollock BE, Gorman DA, Coffey RJ. Patient outcomes after arteriovenous malformation radiosurgical management: results based on a 5- to 14-year follow-up study. Neurosurgery. 2003;52(6):1291-1296; discussion 6-7. PubMed PMID: 12762874.

(64.) Jawahar A, Wadhwa R, Berk C, Caldito G, DeLaune A, Ampil F, et al. Assessment of pain control, quality of life, and predictors of success after gamma knife surgery for the treatment of trigeminal neuralgia. Neurosurg Focus. 2005;18(5):E8. PubMed PMID: 15913284.

(65.) Baschnagel AM, Cartier JL, Dreyer J, Chen PY, Pieper DR, Olson RE, et al. Trigeminal neuralgia pain relief after gamma knife stereotactic radiosurgery. Clin Neurol Neurosurg. 2014;117:107-11. doi: 10.1016/j.clineuro.2013.12.003. PubMed PMID: 24438815.

(66.) Li P, Wang W, Liu Y, Zhong Q, Mao B. Clinical outcomes of 114 patients who underwent gamma-knife radiosurgery for medically refractory idiopathic trigeminal neuralgia. J Clin Neurosci. 2012;19(1):71-74. doi: 10.1016/j.jocn.2011.03.020. PubMed PMID: 22154202.

(67.) Lindquist C, Paddick I. The Leksell Gamma Knife Perfexion and comparisons with its predecessors. Neurosurgery. 2007;61(3 Suppl):130-140; discussion 40-41. doi: 10.1227/01. neu.0000289726.35330.8a. PubMed PMID: 17876243.

Drs. Nanda, Bir, Bollam and Ms. Ward are all associated with the Department of Neurosurgery, LSU Health Sciences Center, Shreveport, LA.
Table 1: Basal characteristics of the patients and number of
different disorders

Variables                              Value

Total no. of surgeries                 1,017
Total no. cases                        911
Age
  Median                               55
  Range                                14-101
Gender
  Male                                 394 (43.2%)
  Female                               517 (56.8%)
Ethnicity
  Caucasians                           687 (75.4%)
  African Americans                    221 (24.2%)
  Asian                                3 (0.3%)
Intracranial lesions treated by GKRS
  Vestibular Schwanomma                82 (9%)
  Meningioma                           136 (14.9%)
  Metastatic brain tumors              298 (32.7%)
  Astrocytoma                          49 (5.3%)
  Pituitary adenoma                    92 (10%)
  AVM                                  85 (9.3%)
  TGN                                  169 (18.5%)

Table 2: Outcomes of GKRS on vestibular schwannoma

                                                     Postop
Parameter                     Preop     Decreased   Unchanged

Radiological Changes
Number of patients              82         44          30
Tumor size                     3.24       1.72        2.93
Time required (mo)                         40          34
KPS Scale                       79                     90
Changes in Neurological Symptoms and Symptoms
  Hearing loss               80 (98%)               16 (20%)
  Facial nerve affection     16 (20%)                5 (6%)
  Ataxia                     22 (27%)                6 (7%)
Complications
Hydrocephalus                   0                       1
Left hemiparesis                0                       2
Trigeminal nerve affection      0                       3

Parameter                    Progressed   p Value

Radiological Changes
Number of patients               8
Tumor size                      4.2
Time required (mo)               29
KPS Scale
Changes in Neurological Symptoms and Symptoms
  Hearing loss                            <0.0001
  Facial nerve affection                   0.001
  Ataxia                                  <0.001
Complications
Hydrocephalus
Left hemiparesis
Trigeminal nerve affection

Table 3: Outcomes of GKRS on meningioma

                                                     Postop
Parameter                     Preop     Decreased   Unchanged

Radiological Changes
  Number of patients           136         69          47
  Tumor size                   5.40       2.05        5.73
  Time required (mo)                       38          34
KPS Scale                       80                     92

Changes in Neurological Sysmptoms and Symptoms

  Imbalance                   6 (4%)                 5 (3%)
  Visual imparement          25 (18%)                7 (5%)
  Trigeminal nerve            4 (3%)                 3 (2%)
  dysfunction
  Facial nerve dysfunction    8 (6%)                 4 (3%)
  Hearing deficit             9 (7%)                 7 (5%)
Complications
Hydrocephalus                   0                       2
Seizure                         0                       5

Parameter                    Progressed   p Value

Radiological Changes
  Number of patients             20
  Tumor size                   11.80
  Time required (mo)             22
KPS Scale

Changes in Neurological Sysmptoms and Symptoms

  Imbalance                                 NS
  Visual imparement                        0.009
  Trigeminal nerve                          NS
  dysfunction
  Facial nerve dysfunction                  NS
  Hearing deficit                           NS
Complications
Hydrocephalus
Seizure

Table 4: Outcomes of GKRS on metastatic brain tumors

Parameter                      Preop       Postop      Postop
                                          Decreased   Unchanged

Radiological Changes
  Number of patients            298          135         91
  Brain edema response                       63          18

Parameter                      Postop      p Value
                             Progressed

Radiological Changes
  Number of patients             72          304
  Brain edema response           40

Prognosis Factors for Improved Survival

                                        95% CI
                                 HR     (lower)   Upper    p Value

  RPA classification            0.28     0.14     0.57     <0.0001
  Hydrocephalus (yes)           4.48     2.17     9.27     <0.0001
  Number of MBTs                1.29     0.92     1.83      0.14
  Extra-cranial metastasis      0.98     0.61     1.57      0.93
  Recurrent tumor               1.53     1.07     2.18      0.01
  Gender                        1.14     0.83     1.57      0.40
  Ethnicity                     0.75     0.53     1.06      0.10
  Age >65yr                     1.26     0.87     1.82      0.21
  KPS                           1.60     1.14     2.25      0.007

Table 5: Outcomes of GKRS in a strocytomas

                                         Postop
Parameter             Preop  Decreased  Unchanged  Progressed  p Value

Radiological Changes
  Number of patients   49        2         10          37

Prognosis Factors for Improved Survival

                       HR     95% CI      Upper                p Value
                              (lower)

  Age >50yr           0.38     0.19       0.78                  0.008
  Gender              1.24     0.62       2.50                  0.54
  KPS                 2.17     1.06       4.44                  0.03
  GKRS at             0.36     0.15       0.87                  0.02
    recurrence vs.
    upfront
  Neurodeficit        2.56     1.22       5.33                  0.01
  Marginal dose       0.58     0.28       1.20                  0.14
  Chemotherapy        1.23     0.57       2.65                  0.59

Table 6: Outcomes of GKRS in pituitary adenomas

                                                    Postop
Parameter                  Preop      Decreased   Unchanged

Radiological Changes
  Number of patients         92          54           32
Tumor size                  5.2         2.93         5.7
Time required (mo)                       45
KPS scale                    87                       94
Changes in neurological symptoms and symptoms
  Visual impairment      46 (64.7%)                 5 (7%)
  Neurodeficits          20 (28.1%)                3 (4.2%)
Complications
  Hypopituitarism                                 11 (15.5%)
  Panhypopituitarism                               3 (4.2%)
  Diabetes insipidus                               1 (1.4%)
  Visual deterioration                             6 (2.8%)
  New CN III palsy                                2. (2.8%)
  Hydrocephalus                                    1 (1.4%)

Parameter                Progressed   p Value

Radiological Changes
  Number of patients         6
Tumor size                  6.60
Time required (mo)           43
KPS scale
Changes in neurological symptoms and symptoms
  Visual impairment
  Neurodeficits
Complications
  Hypopituitarism
  Panhypopituitarism
  Diabetes insipidus
  Visual deterioration
  New CN III palsy
  Hydrocephalus

Table 7: Outcomes of GKRS in AVM

                                       Postop
Parameter                    Preop   Obliterated   Expanded   p Value

Radiological Changes
  Number of patients          85         67           18
  Time Required (mo)                     35           23
Prognosis Factors for Improved Survival
  Gender (male vs. female)                                     0.04
  H/O of hemorrhage                                            0.24
  H/O embolization                                             0.27
  Spetzler-Martin grade                                        0.002
    (grade I-III)
  Presence/absence of                                          0.01
    neurodeficits

Table 8: Outcomes of GKRS in trigeminal neuralgia

Parameter                               Preop   Complete   Postop
                                                 Relief    Partial
                                                           Relief

Radiological Changes
  Number of patients                     169       94        38
Predictors of Pain Relief
  Age [greater than or equal to] 70yr
  Gender
  Pain distribution (V2, 3)
  Ethnicity (Caucasian)

Parameter                               No Relief   p Value

Radiological Changes
  Number of patients                       37
Predictors of Pain Relief
  Age [greater than or equal to] 70yr                0.02
  Gender                                             0.94
  Pain distribution (V2, 3)                          0.31
  Ethnicity (Caucasian)                               .01

Table 9: Summary of overall control of intracranial lesions by GKRS

Parameter             Preop     Postop        Postop      p Value
                              Controlled   Uncontrolled

Intracranial Tumors
  Benign               310    276 (89%)      34 (11%)     <0.0001
  Malignant            347    244 (70%)     103 (30%)     <0.0001
AVM                    85      67 (79%)      18 (21%)     <0.0001
TGN                    169    132 (78%)      37 (22%)     <0.0001
COPYRIGHT 2015 Louisiana State Medical Society
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Bir, Shyamal C.; Ward, Tabitha; Bollam, Papireddy; Nanda, Anil
Publication:The Journal of the Louisiana State Medical Society
Article Type:Report
Date:Mar 1, 2015
Words:6397
Previous Article:Retroperitoneal immature teratoma.
Next Article:Risk factors for HIV acquisition in urban Latinos and implications for prevention.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters